For Healthcare Professionals

company logo
Alt
Alt

Éducation en matière de maladies

VRS: Une maladie courante mais grave chez les personnes âgées

Cette vidéo souligne l'importance de la prévention du VRS chez les patients à haut risque en donnant un aperçu du VRS, de son impact sur les personnes âgées et les personnes présentant certaines comorbidités, ainsi que de la saisonnalité du virus.

Références

  1. Chen R. Slowing down kidney disease. American Kidney Fund. January 10, 2022. Accessed February 17, 2025. https://www.kidneyfund.org/node/1479

  2. Branche AR, Saiman L, Walsh EE, et al. Incidence of respiratory syncytial virus infection among hospitalized adults, 2017-2020. Clin Infect Dis. 2022;74(6):1004-1011.

  3. Centers for Disease Control and Prevention. How RSV spreads. August 30, 2024. Accessed February 13, 2025. https://www.cdc.gov/rsv/causes/index.html

  4. Centers for Disease Control and Prevention. RSV in older adults. August 30, 2024. Accessed February 13, 2025. https://www.cdc.gov/rsv/older-adults/index.html

  5. Crooke SN, Ovsyannikova IG, Poland GA, Kennedy RB. Immunosenescence and human vaccine immune responses. Immun Ageing. 2019;16:25.

  6. Falsey AR, Walsh EE, House S, et al. Risk factors and medical resource utilization of respiratory syncytial virus, human metapneumovirus, and influenza-related hospitalizations in adults—a global study during the 2017-2019 epidemic seasons (Hospitalized Acute Respiratory Tract Infection [HARTI] Study). Open Forum Infect Dis. 2021;8(11):ofab491.

  7. Hamid S, Winn A, Parikh R, et al. Seasonality of respiratory syncytial virus - United States, 2017-2023. MMWR Morb Mortal Wkly Rep. 2023;72(14):355-361.

  8. Li Y, Moser C, Aga E, et al. Immune status and SARS-CoV-2 viral dynamics. J Infect Dis. 2023;228(suppl 2):S111-S116.

  9. McClure DL, Kieke BA, Sundaram ME, et al. Seasonal incidence of medically attended respiratory syncytial virus infection in a community cohort of adults ≥50 years old. PLoS One. 2014;9(7):e102586.

  10. Pandya MC, Callahan SM, Savchenko KG, Stobart CC. A contemporary view of respiratory syncytial virus (RSV) biology and strain-specific differences. Pathogens. 2019;8(2):67.

  11. Papi A, Ison MG, Langley JM, et al. Respiratory syncytial virus prefusion f protein vaccine in older adults. N Engl J Med. 2023;388(7):595-608.

  12. Piedimonte G, Perez MK. Respiratory syncytial virus infection and bronchiolitis. Pediatr Rev. 2014;35(12):519-530.

  13. Respiratory syncytial virus (RSV). National Foundation for Infectious Diseases. September 2024. Accessed February 17, 2025. https://www.nfid.org/infectious-disease/rsv/

  14. Savic M, Penders Y, Shi T, Branche A, Pirçon JY. Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: a systematic literature review and meta-analysis. Influenza Other Respir Viruses. 2023;17(1):e13031.

  15. Tseng HF, Bruxvoort K, Ackerson B, et al. The epidemiology of herpes zoster in immunocompetent, unvaccinated adults ≥50 years old: incidence, complications, hospitalization, mortality, and recurrence. J Infect Dis. 2020;222(5):798-806.

  16. Pyramide des âges StatBel janvier 2023. https://statbel.fgov.be/fr/themes/population/structure-de-la-population (dernière consultation en avril 2025).

  17. Conseil Supérieur de la Santé Avis 9837: Vaccination contre le VRS (adultes). Décembre 2024. https://www.hgr-css.be/fr/avis/9837/vaccination-contre-le-vrs-adultes-revision-2024 (dernière consultation en avril 2025).

L'impact du VRS : Un lourd fardeau pour les patients vulnérables

Cette vidéo met l'accent sur le fardeau global que représente le VRS pour les personnes âgées, les patients à haut risque et les systèmes de soins de santé. Elle examine le rôle du VRS comme cause de maladies des voies respiratoires inférieures, de taux élevés d'hospitalisation, de complications et même de mortalité.

Références

  1. Belongia EA, King JP, Kieke BA, et al. Clinical features, severity, and incidence of RSV illness during 12 consecutive seasons in a community cohort of adults ≥60 years old. Open Forum Infect Dis. 2018;5(12):ofy316.

  2. Branche AR, Saiman L, Walsh EE, et al. Incidence of respiratory syncytial virus infection among hospitalized adults, 2017-2020. Clin Infect Dis. 2022;74(6):1004-1011.

  3. Centers for Disease Control and Prevention. About RSV. August 30, 2024. Accessed February 13, 2025. https://www.cdc.gov/rsv/about/index.html

  4. Centers for Disease Control and Prevention. RSV in older adults. August 30, 2024. Accessed February 13, 2025. https://www.cdc.gov/rsv/older-adults/index.html

  5. Falsey AR, Walsh EE, House S, et al. Risk factors and medical resource utilization of respiratory syncytial virus, human metapneumovirus, and influenza-related hospitalizations in adults—a global study during the 2017-2019 epidemic seasons (Hospitalized Acute Respiratory Tract Infection [HARTI] Study). Open Forum Infect Dis. 2021;8(11):ofab491.

  6. Herring WL, Zhang Y, Shinde V, Stoddard J, Talbird SE, Rosen B. Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States. Vaccine. 2022;40(3):483-493.

  7. Molnar D, La EM, Verelst F, et al. Public health impact of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among older adults in the United States. Infect Dis Ther. 2024;13(4):827-844.

  8. National Foundation for Infectious Diseases. NFID urges action to reduce burden of respiratory syncytial virus (RSV). Accessed February 13, 2025. https://www.nfid.org/nfid-urges-action-to-reduce-burden-of-respiratory-syncytial-virus-rsv/

  9. Nguyen-Van-Tam JS, O’Leary M, Martin ET, et al. Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries. Eur Respir Rev. 2022;31(166):220105.

  10. Presser LD, van den Akker WMR, Meijer A; PROMISE Investigators. Respiratory syncytial virus European Laboratory Network 2022 survey: need for harmonization and enhanced molecular surveillance. J Infect Dis. 2024;229(suppl 1):S34-S39.

  11. Rozenbaum MH, Judy J, Tran D, Yacisin K, Kurosky SK, Begier E. Low levels of RSV testing among adults hospitalized for lower respiratory tract infection in the United States. Infect Dis Ther. 2023;12(2):677-685.

  12. Savic M, Penders Y, Shi T, Branche A, Pirçon JY. Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: a systematic literature review and meta-analysis. Influenza Other Respir Viruses. 2023;17(1):e13031.

  13. Tseng HF, Bruxvoort K, Ackerson B, et al. The epidemiology of herpes zoster in immunocompetent, unvaccinated adults ≥50 years old: incidence, complications, hospitalization, mortality, and recurrence. J Infect Dis. 2020;222(5):798-806.

  14. Volling C, Hassan K, Mazzulli T, et al. Respiratory syncytial virus infection-associated hospitalization in adults: a retrospective cohort study. BMC Infect Dis. 2014;14:665.

  15. Wyffels V, Kariburyo F, Gavart S, Fleischhackl R, Yuce H. A real-world analysis of patient characteristics and predictors of hospitalization among US Medicare beneficiaries with respiratory syncytial virus infection. Adv Ther. 2020;37(3):1203-1217.

VRS: La menace qui pèse sur les plus vulnérables

Cette vidéo met en évidence les risques graves potentiels que le VRS fait courir aux personnes âgées et à celles qui souffrent de comorbidités courantes telles que la BPCO, l'asthme et les maladies cardiovasculaires et le diabète. Elle souligne la probabilité accrue de complications graves, d'hospitalisations et de décès pour ces patients à haut risque.

Références

  1. Ieven, M., et al. (2018). Aetiology of lower respiratory tract infection in adults in primary care: a prospective study in 11 European countries. Clinical Microbiology and Infection, 24(11), 1158-1163. https://doi.org/10.1016/j.cmi.2018.02.004

  2. Savic M et al. Influenza Other Respir Viruses 2023;17(1):e13031.

  3. Pyramide des âges StatBel janvier 2023. https://statbel.fgov.be/fr/themes/population/ structure-de-la-population (dernière consultation en avril 2025).

  4. Conseil Supérieur de la Santé Avis 9725: Vaccination contre le VRS (adultes). Septembre 2023.

  5. Branche AR, Saiman L, Walsh EE, et al. Incidence of respiratory syncytial virus infection among hospitalized adults, 2017-2020. Clin Infect Dis. 2022;74(6):1004-1011

  6. Branche AR, Falsey AR. Respiratory syncytial virus infection in older adults: an under-recognized problem. Drugs Aging. 2015;32(4):261-269

  7. Centers for Disease Control and Prevention. RSV in older adults. August 30, 2024. Accessed February 13, 2025. https://www.cdc.gov/rsv/older-adults/ index.html

  8. Crooke SN, Ovsyannikova IG, Poland GA, Kennedy RB. Immunosenescence and human vaccine immune responses. Immun Ageing. 2019;16:25

  9. Ivey KS, Edwards KM, Talbot HK. Respiratory syncytial virus and associations with cardiovascular disease in adults. J Am Coll Cardiol. 2018;71(14):1574-1583

  10. Klekotka RB, Mizgała E, Król W. The etiology of lower respiratory tract infections in people with diabetes. Pneumonol Alergol Pol. 2015;83(5):401-408

  11. Kujawski SA, Whitaker M, Ritchey MD, et al. Rates of respiratory syncytial virus (RSV)-associated hospitalization among adults with congestive heart failure-United States, 2015-2017. PLoS One. 2022;17(3):e0264890

  12. Linder KA, Malani PN. RSV infection in older adults. JAMA. 2023;330(12):1200

  13. Osei-Yeboah R, Zhu F, Wang X, Nair H, Campbell H. Respiratory syncytial virus-associated hospital admissions by deprivation levels among children and adults in Scotland. J Infect Dis. 2024;229(suppl 1):S61-S69

  14. Tseng HF, Bruxvoort K, Ackerson B, et al. The epidemiology of herpes zoster in immunocompetent, unvaccinated adults ≥50 years old: incidence, complications, hospitalization, mortality, and recurrence. J Infect Dis. 2020;222(5):798-806

VRS: L'impact du VRS et de la grippe sur les personnes à risque

Cette vidéo explore les similitudes entre le VRS et la grippe, y compris leurs symptômes et leurs complications, dans le but de sensibiliser et de souligner l'importance des tests diagnostiques et de la prévention de ces deux virus.

Références

  1. Ackerson B, Tseng HF, Sy LS, et al. Severe morbidity and mortality associated with respiratory syncytial virus versus influenza infection in hospitalized older adults. Clin Infect Dis. 2019;69(2):197-203.

  2. Branche AR, Falsey AR. Respiratory syncytial virus infection in older adults: an under-recognized problem. Drugs Aging. 2015;32(4):261-269.

  3. Branche AR, Saiman L, Walsh EE, et al. Incidence of respiratory syncytial virus infection among hospitalized adults, 2017-2020. Clin Infect Dis. 2022;74(6):1004-1011.

  4. Centers for Disease Control and Prevention. Diagnosis for flu. October 3, 2022. Accessed February 13, 2025. https://www.cdc.gov/flu/testing/index.html

  5. Centers for Disease Control and Prevention. How RSV spreads. August 30, 2024. Accessed February 13, 2025. https://www.cdc.gov/rsv/causes/index.html

  6. Centers for Disease Control and Prevention. Overview of influenza testing methods. August 8, 2024. Accessed February 13, 2025. https://www.cdc.gov/flu/hcp/testing-methods/index.html

  7. Centers for Disease Control and Prevention. Preventing respiratory viruses. March 1, 2024. Accessed February 17, 2025. https://www.cdc.gov/respiratory-viruses/prevention/index.html

  8. Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev. 2000;13(3):371-384.

  9. Falsey AR, Walsh EE, House S, et al. Risk factors and medical resource utilization of respiratory syncytial virus, human metapneumovirus, and influenza-related hospitalizations in adults—a global study during the 2017-2019 epidemic seasons (Hospitalized Acute Respiratory Tract Infection [HARTI] Study). Open Forum Infect Dis. 2021;8(11):ofab491.

  10. Labcorp. COVID-19, flu and RSV testing information and resources. Accessed February 13, 2025. https://www.labcorp.com/patient-covid-flu-rsv

  11. Maggi S, Veronese N, Burgio M, et al. Rate of hospitalizations and mortality of respiratory syncytial virus infection compared to influenza in older people: a systematic review and meta-analysis. Vaccines (Basel). 2022;10(12):2092.

  12. National Foundation for Infectious Diseases. Respiratory Syncytial Virus in Older Adults: A Hidden Annual Epidemic. National Foundation for Infectious Diseases; 2016.

  13. Onwuchekwa C, Moreo LM, Menon S, et al. Underascertainment of respiratory syncytial virus infection in adults due to diagnostic testing limitations: a systematic literature review and meta-analysis. J Infect Dis. 2023;228(2):173-184.

  14. Pandya MC, Callahan SM, Savchenko KG, Stobart CC. A contemporary view of respiratory syncytial virus (RSV) biology and strain-specific differences. Pathogens. 2019;8(2):67.

  15. Presser LD, van den Akker WMR, Meijer A; PROMISE Investigators. Respiratory syncytial virus European Laboratory Network 2022 survey: need for harmonization and enhanced molecular surveillance. J Infect Dis. 2024;229(suppl 1):S34-S39.

  16. Rozenbaum MH, Judy J, Tran D, Yacisin K, Kurosky SK, Begier E. Low levels of RSV testing among adults hospitalized for lower respiratory tract infection in the United States. Infect Dis Ther. 2023;12(2):677-685.

  17. Savic M, Penders Y, Shi T, Branche A, Pirçon JY. Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: a systematic literature review and meta-analysis. Influenza Other Respir Viruses. 2023;17(1):e13031.

  18. Tseng HF, Bruxvoort K, Ackerson B, et al. The epidemiology of herpes zoster in immunocompetent, unvaccinated adults ≥50 years old: incidence, complications, hospitalization, mortality, and recurrence. J Infect Dis. 2020;222(5):798-806.

  19. Vos LM, Bruning AHL, Reitsma JB, et al. Rapid molecular tests for influenza, respiratory syncytial virus, and other respiratory viruses: a systematic review of diagnostic accuracy and clinical impact studies. Clin Infect Dis. 2019;69(7):1243-1253.

  20. Widmer K, Zhu Y, Williams JV, Griffin MR, Edwards KM, Talbot HK. Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults. J Infect Dis. 2012;206(1):56-62.

BPCO = Bronchopneumopathie chronique obstructive; VRS = virus respiratoire syncytial

Articles en lien

image

Vous cherchez plus d'informations sur le VRS ?

Découvrez des ressources pour vous aider à orienter vos conversations avec les patients.

LIRE LA SUITE
image

Comment aider à protéger les adultes contre l'infection par le VRS?

En savoir plus sur les moyens de prévenir une infection par le VRS.

LIRE LA SUITE
image

Quels sont les symptômes courants de l'infection au VRS ?

Apprenez à reconnaître les symptômes de l'infection au VRS et comment elle est diagnostiquée.

LIRE LA SUITE
Vos choix en matière de confidentialité
company logo
ER: GlaxoSmithKline Pharmaceuticals s.a./n.v.
Avenue Fleming 20, 1300 Wavre Belgique.
NP-BE-RSA-WCNT-250007 - Mars 2025
Ce site web est destiné uniquement aux professionnels de la santé de Belgique et du Grand-Duché de Luxembourg.